BRPI0412697A - composições farmacêuticas que apresentam um revestimento expansìvel - Google Patents

composições farmacêuticas que apresentam um revestimento expansìvel

Info

Publication number
BRPI0412697A
BRPI0412697A BRPI0412697-1A BRPI0412697A BRPI0412697A BR PI0412697 A BRPI0412697 A BR PI0412697A BR PI0412697 A BRPI0412697 A BR PI0412697A BR PI0412697 A BRPI0412697 A BR PI0412697A
Authority
BR
Brazil
Prior art keywords
expandable coating
pharmaceutical compositions
expandable
coating
pharmaceutical
Prior art date
Application number
BRPI0412697-1A
Other languages
English (en)
Inventor
Irukulla Srinivas
Akhilesh Ashok Dixit
Pallempalli Venkata Silv Reddy
Billa Praveen Reddy
Mailatur Sivaraman Mohan
Kodipyaka Ravinder
Vijay Nasare
Edward D Pergament
Original Assignee
Reddys Lab Inc Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reddys Lab Inc Dr filed Critical Reddys Lab Inc Dr
Publication of BRPI0412697A publication Critical patent/BRPI0412697A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846Poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/2873Proteins, e.g. gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5026Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5036Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5052Proteins, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"COMPOSIçõES FARMACêUTICAS QUE APRESENTAM UM REVESTIMENTO EXPANSìVEL". Uma forma de dosagem farmacêutica contendo um ativo farmacêutico que não é estável na presença de ácido compreende um núcleo contendo o ativo e um desintegrante, um revestimento expansível ao redor do núcleo, e um revestimento entérico ao redor do revestimento expansível.
BRPI0412697-1A 2003-07-17 2004-07-16 composições farmacêuticas que apresentam um revestimento expansìvel BRPI0412697A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN580CH2003 2003-07-17
IN1064CH2003 2003-12-30
US56370704P 2004-04-20 2004-04-20
PCT/US2004/022910 WO2005009410A2 (en) 2003-07-17 2004-07-16 Pharmaceutical compositions having a swellable coating

Publications (1)

Publication Number Publication Date
BRPI0412697A true BRPI0412697A (pt) 2006-10-03

Family

ID=34108415

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0412697-1A BRPI0412697A (pt) 2003-07-17 2004-07-16 composições farmacêuticas que apresentam um revestimento expansìvel

Country Status (12)

Country Link
EP (1) EP1651193A2 (pt)
JP (1) JP2007524646A (pt)
KR (1) KR20060065632A (pt)
AU (1) AU2004259226B2 (pt)
BR (1) BRPI0412697A (pt)
CA (1) CA2532310A1 (pt)
HR (1) HRP20060016A2 (pt)
IL (1) IL173053A0 (pt)
MX (1) MXPA06000577A (pt)
NO (1) NO20060786L (pt)
NZ (1) NZ544608A (pt)
WO (1) WO2005009410A2 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050147663A1 (en) * 2003-07-17 2005-07-07 Mohan Mailatur S. Method of treatment for improved bioavailability
FR2878159B1 (fr) * 2004-11-24 2008-10-17 Flamel Technologies Sa Medicament oral a liberation modifiee d'au moins un principe actif sous forme multimicrocapsulaire
CA2608444A1 (en) * 2005-05-13 2007-03-15 Combino Pharm, S.L. Formulations containing pantoprazole free acid and its salts
EA015535B1 (ru) * 2005-07-11 2011-08-30 Никомед Данмарк Апс Формуляция бензимидазола
EP1973532A1 (en) * 2006-01-16 2008-10-01 Jubilant Organosys Limited Stable pharmaceutical formulation of an acid labile compound and process for preparing the same
US9241910B2 (en) 2008-03-11 2016-01-26 Takeda Pharmaceutical Company Limited Orally-disintegrating solid preparation
EP2319504A1 (en) * 2009-11-07 2011-05-11 Laboratorios Del. Dr. Esteve, S.A. Pharmaceutical solid dosage form
WO2012001705A2 (en) * 2010-06-29 2012-01-05 Cadila Healthcare Limited Pharmaceutical compositions of (r)-lansoprazole
EP2950790A4 (en) * 2012-08-09 2018-04-25 Dynamis Therapeutics, Inc. Methods for maintaining or improving health, well-being and/or a physiological function in a subject
JP6856326B2 (ja) * 2016-07-15 2021-04-07 富士化学工業株式会社 腸放出粒子組成物
KR101907116B1 (ko) * 2016-07-25 2018-10-11 한미약품 주식회사 에스오메프라졸, 또는 약학적으로 허용 가능한 그의 염을 포함하는, pH-의존성 약물 방출 특성이 개선된 제형
KR101877350B1 (ko) * 2016-10-28 2018-08-09 한미약품 주식회사 에스오메프라졸 함유 복합 캡슐제 및 그 제조방법
JP6336651B1 (ja) * 2016-12-15 2018-06-06 大原薬品工業株式会社 化学的安定性が改善されたエソメプラゾール塩を含有する錠剤
JP7026510B2 (ja) * 2018-01-11 2022-02-28 株式会社Screenホールディングス 印刷物、読取装置、読取方法、印刷方法、および印刷装置
CN111728124A (zh) * 2020-07-08 2020-10-02 江苏宏远药业有限公司 一种安全性较高的食品级白色素

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US341338A (en) * 1886-05-04 Blind
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
YU48263B (sh) * 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
EP0833617A1 (en) * 1995-06-20 1998-04-08 Pharma-Vinci A/S A method of preparing an oral preparation provided on the outer side with an enteric coating, as well as an oral preparation obtained by the method
ATE262332T1 (de) * 1995-09-21 2004-04-15 Pharma Pass Ii Llc Lansoprazolhaltige arzneizusammensetzung und herstellungsverfahren
US6296876B1 (en) * 1997-10-06 2001-10-02 Isa Odidi Pharmaceutical formulations for acid labile substances
US6500459B1 (en) * 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
US6635206B1 (en) * 2000-05-03 2003-10-21 The Board Of Trustees Of The University Of Illinois Method of manufacturing improved corn zein resin films, sheets, and articles
US6368628B1 (en) * 2000-05-26 2002-04-09 Pharma Pass Llc Sustained release pharmaceutical composition free of food effect
PE20050150A1 (es) * 2003-05-08 2005-03-22 Altana Pharma Ag Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo

Also Published As

Publication number Publication date
MXPA06000577A (es) 2006-07-03
NO20060786L (no) 2006-04-10
EP1651193A2 (en) 2006-05-03
WO2005009410A3 (en) 2005-05-19
WO2005009410A2 (en) 2005-02-03
NZ544608A (en) 2008-07-31
HRP20060016A2 (en) 2006-02-28
AU2004259226A1 (en) 2005-02-03
CA2532310A1 (en) 2005-02-03
IL173053A0 (en) 2006-06-11
KR20060065632A (ko) 2006-06-14
AU2004259226B2 (en) 2009-09-24
JP2007524646A (ja) 2007-08-30

Similar Documents

Publication Publication Date Title
BRPI0412697A (pt) composições farmacêuticas que apresentam um revestimento expansìvel
RS49982B (sr) Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2
EA200600598A1 (ru) Лекарственные формы замедленного высвобождения
BRPI0108478B8 (pt) composição nutritiva contendo substancias pré-bióticas
RS51563B (en) PHARMACEUTICAL COMPOSITIONS CONTAINING ROOSUVASTATIN CALCIUM
BR0109925A (pt) Composição de revestimento para mascaramento de paladar
HUP0302991A3 (en) Isoxazoles and their use as inhibitors of erk and pharmaceutical compositions containing the compounds
SE9500422D0 (sv) New oral pharmaceutical dosage forms
DK1276470T3 (da) Smagskaskerende overtrækssammensætning
MX2007006212A (es) Medicamento oral para liberacion modificada de al menos un principio activo bajo forma multimicrocapsular.
BR0015188A (pt) Composições farmacêuticas
BR0109943A (pt) Composições farmacêuticas
AR046970A1 (es) Esteres de fosfato de florfenicol
PA8529501A1 (es) Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa -7."
RS50534B (sr) Intranazalna formulacija rotigotina
UY27352A1 (es) Formulacion de iniciacion rápida
AR034900A1 (es) Uso de una cantidad eficaz de un inhibidor de pde4 y un agente anticolinergico, bien en forma combinada sola o por separado, composiciones farmaceuticas que los comprenden, metodo para prepararlas, y uso de una composicion que comprende una cantidad eficaz de un inhibidor de pde4, una cantidad efica
RS54050B1 (en) FORMULATIONS AND METHODS FOR THE TREATMENT OF AMYLOIDOSIS
AR023789A1 (es) Composicion farmaceutica en forma unitaria que contiene acido acetilsalicilico y hidrogenosulfato de clopidogrel
ATE260650T1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
ES2196620T3 (es) Formulacion de liberacion prolongada que contiene venlafaxina.
BR0202491A (pt) Forma de dosagem de núcleo macio, de revestimento frágil
AP2003002716A0 (en) Medicinal compositions containing propenone derivatives.
BRPI0414305A (pt) sistema de liberação de drogas por via oral
NZ522242A (en) Use of 13-hode as a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: CONFORME ARTIGO 10O DA RESOLUCAO 124/06, CABE SER ARQUIVADO REFERENTE AO NAO RECOLHIMENTO DA 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2143 DE 31/01/2012.